SynthesisJournal of patient-reported outcomes2026
A systematic review of financial toxicity measurement instruments for cancer patients based on the COSMIN guideline.
Synthesis in Journal of patient-reported outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveFinancial toxicity, characterized by the financial burden and psychological distress associated with cancer treatment, has become a critical issue impacting patient outcomes and quality of life. This study aimed to conduct an updated and comprehensive systematic review to evaluate the methodological quality and measurement properties of financial toxicity measurement instruments for cancer patients, thereby guiding the selection of high-quality tools for future empirical research.
methodsLiterature on financial toxicity measurement instruments for cancer patients was retrieved from CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, CINAHL, Scopus, and Embase databases, with a search range from the inception up to April 16, 2025. Two researchers independently screened the literature and extracted data. The included studies were assessed using the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN), and recommendations were formulated based on the quality of evidence and measurement properties.
resultsA total of eighteen studies were included, involving eight financial toxicity measurement instruments for cancer patients. None of the studies reported measurement error. The Comprehensive Score for Financial Toxicity (COST), Financial Index of Toxicity (FIT), and Subjective Financial Distress Questionnaire (SFDQ) were provisionally recommended for use (Category B), while the other five instruments were not recommended due to insufficient evidence (Category C).
conclusionThe COST is provisionally recommended for measuring financial toxicity in cancer patients. The methodological quality and measurement properties of existing financial toxicity instruments still require further improvement. Future research should adhere strictly to the COSMIN guideline to validate existing tools or develop new, high-quality instruments with comprehensive evaluations of their measurement properties.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.